According to our new market research study titled” Late Stage Chronic Kidney Disease Drugs Market – Global Analysis and Forecast by Product Type, Indication and Distribution Channel” the global late stage chronic kidney disease drugs market is expected to reach US$ 11,096.9 million by 2027 from US$ 4,680.0 million in 2019; it is estimated to grow at a CAGR of 11.6% from 2020 to 2027. The report highlights the trends prevalent in the global late stage chronic kidney disease drugs market, and the drivers and deterrents pertaining to its growth.
Late-stage renal disease, also called end-stage kidney disease, occurs when chronic kidney disease (the gradual loss of kidney function) reaches an advanced state. In end-stage renal disease, kidneys are no longer able to work as they should to meet the body’s needs. At this advanced stage, the kidney loses all its ability to function effectively, and eventually dialysis or a kidney transplant is needed to save the life. High prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs are the major factor propelling the market growth. However, delay in the diagnosis of chronic kidney disease is expected to hamper the growth of the market up to certain extent during the forecast period.
Download Sample PDF at https://www.theinsightpartners.com/sample/TIPRE00013768/
AbbVie Inc.; Amgen; AstraZeneca; Sanofi; Kyowa Kirin Co., Ltd.; Takeda Pharmaceutical Company Limited; Astellas Pharma Inc.; Bayer AG; Vifor Pharma Management Ltd.; and Akebia Drugs, Inc. are among the prominent players operating in the late stage chronic kidney disease drugs market. The market players are focused on organic strategies to sustain their position in the market. For instance, in Jul-2020, Bayer announced positive results from the Phase III FIDELIO-DKD study, assessing the efficacy and safety of finerenone versus placebo when added to standard of care for chronic kidney disease (CKD) in patients with type 2 diabetes (T2D), has met its primary endpoint.
Chronic kidney disease (CKD) is a common and life-threatening condition that affects 1 in 10 people worldwide. It affects more than 26 million Americans and millions more worldwide. High blood pressure and diabetes were the two major causes in 75% of kidney failure cases between 2015 and 2017. 47% of new end-stage kidney disease (ESKD) patients had a primary diagnosis of diabetes, while 29% of new end-stage kidney disease patients had a primary diagnosis of hypertension. Moreover, according to Bayer’s press release, about 29 million people in the US have type 2 diabetes, and 40% will develop CKD in the coming year.
Based on product type, the late stage chronic kidney disease drugs market is segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others. The calcimimetics segment held the highest share of the late stage chronic kidney disease drugs market in 2019 and is estimated to register the highest CAGR of 12.1% in the market during the forecast period. Factors such as high prevalence of hyperparathyroidism, increased research studies on calcimimetics are some of the impacting factors which drive the segment growth. For instance, in February 2017, Amgen received the US Food and Drug Administration (FDA) approval for Parsabiv, an etelcalcetide, for the treatment of secondary hyperparathyroidism (HPT) in adult patients with late stage chronic kidney disease receiving hemodialysis. Parsabiv is the first therapy approved for HPT in ESRD in 12 years. It is the only calcimimetic that is used for intravenous administration by the dialysis health care team thrice a week to the ending of the hemodialysis session.
Speak to Analyst @ https://www.theinsightpartners.com/speak-to-analyst/TIPRE00013768
According to the CDC, 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure might have chronic kidney disease. In 2015, 30.3 million people in the US had diabetes as per the American Diabetes Association (ADA). According to the CDC, in 2014, around 118,000 people in the US have started the treatment for end-stage renal disease, and the number of people for treatment is expected to increase as more people become aware of this condition. Moreover, the CDC states that around 96% of the people with kidney damage are not aware of having chronic kidney disease, which indicates the underlying market prospective in the late stage of chronic kidney disease drugs. These factors are expected to enhance market growth during the forecast period.
The market growth is also attributed to a few key factors such as high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs. However, delay in the diagnosis of chronic kidney disease is expected to hamper the growth of the market up to certain extent during the forecast period.
Get a Full Report Copy @ https://www.theinsightpartners.com/buy/TIPRE00013768/
The Report Segments the Global Late Stage Chronic Kidney Disease Drugs Market as Follows:
By Product Type
- Vitamin D
- Potassium Binders
- Calcium-Based Phosphate Binders
- Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
- Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
- Late Stage Chronic Kidney Disease Induced Hyperkalaemia
By Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.
Contact Person : Sameer Joshi .
Phone : +1-646-491-9876
E-mail : email@example.com